JP2015530382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530382A5 JP2015530382A5 JP2015529120A JP2015529120A JP2015530382A5 JP 2015530382 A5 JP2015530382 A5 JP 2015530382A5 JP 2015529120 A JP2015529120 A JP 2015529120A JP 2015529120 A JP2015529120 A JP 2015529120A JP 2015530382 A5 JP2015530382 A5 JP 2015530382A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticle formulation
- fatty acid
- nanoparticle
- acid
- phospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 27
- 238000009472 formulation Methods 0.000 claims 25
- 239000003814 drug Substances 0.000 claims 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 230000007935 neutral effect Effects 0.000 claims 8
- 150000004666 short chain fatty acids Chemical class 0.000 claims 7
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000006185 dispersion Substances 0.000 claims 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 5
- 150000003904 phospholipids Chemical class 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- -1 cationic cholesterol derivative Chemical class 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 239000011724 folic acid Substances 0.000 claims 3
- 229960000304 folic acid Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000003929 folic acid group Chemical group 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920000768 polyamine Polymers 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 150000001841 cholesterols Chemical class 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 150000004665 fatty acids Chemical group 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000010120 metabolic dysregulation Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1215289.8A GB201215289D0 (en) | 2012-08-28 | 2012-08-28 | Nanoparticle formulation |
| GB1215289.8 | 2012-08-28 | ||
| PCT/GB2013/052258 WO2014033453A1 (en) | 2012-08-28 | 2013-08-28 | Nanoparticle formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530382A JP2015530382A (ja) | 2015-10-15 |
| JP2015530382A5 true JP2015530382A5 (OSRAM) | 2016-10-13 |
| JP6483017B2 JP6483017B2 (ja) | 2019-03-13 |
Family
ID=47045497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015529120A Active JP6483017B2 (ja) | 2012-08-28 | 2013-08-28 | ナノ粒子製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10201499B2 (OSRAM) |
| EP (1) | EP2890365B1 (OSRAM) |
| JP (1) | JP6483017B2 (OSRAM) |
| CN (1) | CN104837482B (OSRAM) |
| AU (1) | AU2013308245B2 (OSRAM) |
| CA (1) | CA2882705C (OSRAM) |
| GB (1) | GB201215289D0 (OSRAM) |
| WO (1) | WO2014033453A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| US20160158174A1 (en) * | 2014-12-09 | 2016-06-09 | Intercontinental Great Brands Llc | Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients |
| EP3247342A4 (en) * | 2015-01-23 | 2018-10-10 | Temple University - Of The Commonwealth System of Higher Education | Use of short chain fatty acids in cancer prevention |
| CN106551902B (zh) | 2015-09-17 | 2020-07-03 | 阿赖耶识（上海）生物技术有限公司 | 一种高稳定的非囊泡型纳米颗粒及其在治疗微生物感染中的应用 |
| CN105669964B (zh) * | 2016-03-04 | 2017-11-21 | 博瑞生物医药（苏州）股份有限公司 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
| US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
| US20210137838A1 (en) * | 2017-03-13 | 2021-05-13 | Sdg, Inc. | Lipid-based nanoparticles with enhanced stability |
| US11077173B2 (en) | 2017-03-13 | 2021-08-03 | Sdg, Inc. | Lipid-based nanoparticles and methods using same |
| AU2018255269B2 (en) | 2017-04-17 | 2023-03-09 | The University Of Chicago | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease |
| CN107049954A (zh) * | 2017-06-12 | 2017-08-18 | 杭州普施康生物科技有限公司 | 一种药物组合及其制备方法和用途 |
| CN110192651A (zh) * | 2019-05-31 | 2019-09-03 | 浙江工业大学 | 一种利用大豆分离蛋白负载植物甾醇酯的纳米乳液的制备方法 |
| CN111426659B (zh) * | 2020-03-24 | 2023-06-06 | 深圳唯公生物科技有限公司 | 磁性荧光编码微球及其制备方法 |
| WO2023205810A2 (en) * | 2022-04-22 | 2023-10-26 | University Of Virginia Patent Foundation | Nano-enhanced vaccine |
| KR20250107214A (ko) * | 2022-11-10 | 2025-07-11 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 간질환 또는 간장애의 치료 또는 예방 방법 |
| CN118105524B (zh) * | 2024-03-14 | 2024-11-22 | 南京鼓楼医院 | 一种靶向肠上皮细胞的焦亡抑制剂药物递送系统及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| WO1997045442A1 (en) * | 1996-05-24 | 1997-12-04 | Imperial College Of Science Technology And Medicine | Polycationic sterol derivatives as transfection agents |
| US6146847A (en) * | 1996-11-01 | 2000-11-14 | Genespan Corporation | Stabilized transient gene expression |
| IT1303787B1 (it) * | 1998-11-25 | 2001-02-23 | Maria Rosa Gasco | "nanosfere lipidiche solide atte ad una rapida internalizzazione nellecellule" |
| ES2302391T3 (es) | 1998-12-18 | 2008-07-01 | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY, LTD. | Procedimiento de administracion de un compuesto a celulas resistentes a multi-farmacos. |
| US6387952B1 (en) | 2000-09-19 | 2002-05-14 | Arco Chemical Technology L.P. | Method of treating gastrointestinal disorders, particularly colitis |
| WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| WO2006007634A1 (en) | 2004-07-16 | 2006-01-26 | Cerylid Biosciences Ltd | Processes and intermediates |
| WO2006076734A2 (en) | 2005-01-14 | 2006-07-20 | Medical College Of Georgia Research Institute | Prodrugs of short-chain fatty acids and treatment methods |
| WO2006127977A1 (en) * | 2005-05-24 | 2006-11-30 | The Johns Hopkins University | Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof |
| ITMI20051024A1 (it) | 2005-06-01 | 2006-12-02 | Maria Rosa Gasco | Nuovo uso di nanoparticelle lipidiche solide |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| CA2673622A1 (en) * | 2006-12-22 | 2008-07-03 | Imuthes Limited | Lipid |
| TW201019969A (en) * | 2008-11-17 | 2010-06-01 | Enzon Pharmaceuticals Inc | Branched cationic lipids for nucleic acids delivery system |
-
2012
- 2012-08-28 GB GBGB1215289.8A patent/GB201215289D0/en not_active Ceased
-
2013
- 2013-08-28 CN CN201380055336.1A patent/CN104837482B/zh active Active
- 2013-08-28 EP EP13760080.5A patent/EP2890365B1/en active Active
- 2013-08-28 WO PCT/GB2013/052258 patent/WO2014033453A1/en not_active Ceased
- 2013-08-28 JP JP2015529120A patent/JP6483017B2/ja active Active
- 2013-08-28 US US14/424,332 patent/US10201499B2/en active Active
- 2013-08-28 CA CA2882705A patent/CA2882705C/en active Active
- 2013-08-28 AU AU2013308245A patent/AU2013308245B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015530382A5 (OSRAM) | ||
| TWI699354B (zh) | 陽離子性脂質 | |
| EP1993365B1 (en) | Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders | |
| ES2883290T3 (es) | Composición farmacéutica para el suministro de un fármaco aniónico | |
| JP6762094B2 (ja) | 薬剤のデリバリーのためのジスルフィド化合物 | |
| US7741357B1 (en) | Heterocyclic and carbonate derivatives of NDGA and their use as new anti-HIV and anti-cancer agents | |
| JP2013519653A5 (OSRAM) | ||
| CN101506143A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的对乙酰氨基酚及其相关化合物的前药 | |
| BR112015015858B1 (pt) | Uso de uma composição farmacêutica de solução sólida no tratamento de uma inflamação crônica | |
| CN102014870A (zh) | 活性的一氧化氮供体及其制备和应用的方法 | |
| Kalhapure et al. | Oleodendrimers: A novel class of multicephalous heterolipids as chemical penetration enhancers for transdermal drug delivery | |
| JP2014515407A5 (OSRAM) | ||
| JP6744429B2 (ja) | 化合物及びその応用、並びに白金錯体及びそのリポソーム | |
| AU2023420649A1 (en) | Compound for delivering drug, and liposome and drug carrier | |
| CN110433292A (zh) | 一种双靶向材料及其在药物传递中的应用 | |
| US8440641B2 (en) | Phthalocyanine salt formulations | |
| JP2025504405A (ja) | 生分解性エステル結合を含むイオン化可能な脂質およびこれを含む脂質ナノ粒子 | |
| JP2024543272A (ja) | マルチモチーフデンドロン及びその超分子構造ならびにその使用 | |
| JP7179154B2 (ja) | ウイルス送達用ポリマーナノ粒子組成物及びその製造方法 | |
| US20220249376A1 (en) | Nanovesicles and its use for nucleic acid delivery | |
| WO2024017254A1 (zh) | 氨基脂质化合物、其制备方法和应用 | |
| JP2025504802A (ja) | 生分解性ジスルフィド結合を含むイオン化可能な脂質およびこれを含む脂質ナノ粒子 | |
| CN105944120B (zh) | 一种载有十二硼烷马来酰亚胺丙酰哌嗪七甲川菁硫醚盐的叶酸脂质体及其制备方法和应用 | |
| CN116211831A (zh) | 脂质基质局部注射制剂 | |
| Miao et al. | Constructing natural phenolic acid mesopores to enhance chemotherapy and reduce accompanied intestinal damage |